TITLE

Induction immunosuppressive therapies in renal transplantation

AUTHOR(S)
Gabardi, Steven; Martin, Spencer T.; Roberts, Keri L.; Grafals, Monica
PUB. DATE
February 2011
SOURCE
American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p211
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Induction immunosuppressive therapies for patients undergoing renal transplantation are reviewed. Summary. The goal of induction therapy is to prevent acute rejection during the early posttransplantation period by providing a high degree of immunosuppression at the time of transplantation. Induction therapy is often considered essential to optimize outcomes, particularly in patients at high risk for poor short-term outcomes. All of the induction immunosuppressive agents currently used are biological agents and are either monoclonal (muromonab-CD3, daclizumab, basiliximab, alemtuzumab) or polyclonal (antithymocyte globulin [equine] or antithymocyte globulin [rabbit]) antibodies. Although antithymocyte globulin (rabbit) is not labeled for induction therapy, it is used for this purpose more than any other agent. Basiliximab is not considered as potent an immunosuppressive agent but has a much more favorable adverse-effect profile compared with antithymocyte globulin (rabbit) and is most commonly used in patients at low risk for acute rejection. Rituximab is being studied for use as induction therapy but to date has not demonstrated any significant benefits over placebo. While head-tohead data are available comparing most induction agents, the final decision on the most appropriate induction therapy for a transplant recipient is highly dependent on preexisting medical conditions, donor characteristics, and the maintenance immunosuppressive regimen to be used. Conclusion. No standard induction immunosuppressive regimen exists for patients undergoing renal transplantation. Antithymocyte globulin (rabbit) is the most commonly used agent, whereas basiliximab appears safer. The choice of regimen depends on the preferences of clinicians and institutions.
ACCESSION #
57657491

 

Related Articles

  • Severe hypogammaglobulinaemia and opportunistic infections after rituximab therapy in a renal transplant recipient. Kahveci, Arzu; Asicioglu, Ebru; Ari, Elif; Arikan, Hakki; Tuglular, Serhan; Ozener, Cetin // Nephrology Dialysis Transplantation;Apr2010, Vol. 25 Issue 4, p165 

    Infectious complications are the leading causes of morbidity and mortality among renal transplant recipients. Hypogammaglobulinaemia may develop as a result of immunosuppressive therapy and is associated with an increased risk of opportunistic infections particularly in the 6-month...

  • Ä°ntraepidermal Otoimmün Büllöz Hastalıkların Tedavisi. Kaya, Tamer İrfan // Archives of the Turkish Dermatology & Venerology / Turkderm;2011 Supplement 1, Vol. 45, p44 

    Pemfigus is an autoimmune bullous skin disease, characterized by intraepidermal blisters. It is a severe and potentially life-threatening chronic disease with blisters and erosions on the mucosae and the skin. Treatment options do not differ for two most common types of pemphigus, pemphigus...

  • Current trends in immunosuppressive therapies for renal transplant recipients. Lee, Ruth-Ann; Gabardi, Steven // American Journal of Health-System Pharmacy;11/15/2012, Vol. 69 Issue 22, p1961 

    Purpose. Current trends in immunosuppressivetherapies for renal transplant recipients are reviewed.Summary. The common premise for immunosuppressive therapies in renal transplantation is to use multiple agents to work on different immunologic targets.The use of a multidrug regimen allows for...

  • Front-line immunosuppressive treatment of acquired aplastic anemia. Dufour, C; Svahn, J; Bacigalupo, A // Bone Marrow Transplantation;Feb2013, Vol. 48 Issue 2, p174 

    In this article, front-line immunosuppressive therapy (IST) for acquired plastic anemia (AA) is illustrated and discussed. Also second-line and salvage options are briefly illustrated. First-line IST should consist of horse anti-thymocyte globulin (ATG) and CsA that has been shown to result in...

  • Should we consider MMF therapy after rituximab for nephrotic syndrome? Filler, Guido; Huang, Shih-Han; Sharma, Ajay // Pediatric Nephrology;Oct2011, Vol. 26 Issue 10, p1759 

    The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum...

  • Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. Ekberg, Henrik; Tedesco-Silva, Helio; Demirbas, Alper; V�tko, �tefan; Nashan, Bj�rn; G�rkan, Alp; Margreiter, Raimund; Hugo, Christian; Griny�, Josep M.; Frei, Ulrich; Vanrenterghem, Yves; Daloze, Pierre; Halloran, Philip F. // New England Journal of Medicine;12/20/2007, Vol. 357 Issue 25, p2562 

    Background: Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens. Methods: We randomly assigned 1645 renal-transplant recipients to receive...

  • Comparison of tacrolimus with a cyclosporine microemulsion for immunosuppressive therapy in kidney transplantation. Ekmekçioğlu, Ozan; Turkan, Sadi; Yıldız, Şener; Ender Güneş, Zeki // Turkish Journal of Urology;Mar2013, Vol. 39 Issue 1, p16 

    Objective: To compare the efficacy and side effects of a cyclosporine microemulsion and tacrolimus in kidney transplantation immunosuppressive therapy.Materials and methods: Between March 2003 and June 2005, the patients who had undergone kidney tx surgery and who were administered either...

  • Outcome of pediatric cadaveric renal transplantation: A 10 year study. JOHNSON, ROBERT W. G.; WEBB, NICHOLAS J. A.; LEWIS, MALCOLM A.; POSTLETHWAITE, ROBERT J.; DYER, PHIL A.; CONNOLLY, JOHN K. // Kidney International Supplement;Jan1996, Issue 53, pS-72 

    This report deals with 120 cadaveric renal transplants performed in 101 pediatric recipients in this Centre in two five-year periods, 1984 to 1988 (N = 65) and 1989 to 1993 (N = 55). In the first group transplants were allocated on the basis of best size (small donors for small recipients); in...

  • Immunosuppressants.  // Reactions Weekly;9/3/2011, Issue 1367, p23 

    The article describes the clinical cases of four renal transplant patients who developed malignancies associated with their disused arteriovenous fistulae (AVF) while under immunosuppressant therapies.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics